My thesis for Sagimet Biosciences Inc. (NASDAQ: SGMT ) is pretty straightforward: this is a small-cap biotech with a very novel mechanism. Blocking fatty acid synthase could give it a real edge in the MASH market. Denifanstat hasI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foundation gave me an app ...